To the Editor: Empagliflozin and progression of kidney disease in Type 2 diabetes

New England Journal of Medicine

Volumn 375, Issue 18, 2016, Pages 1800-1801

  Parving, Hans Henrik ^a   Lambers Heerspink, Hiddo ^b   De Zeeuw, Dick ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EMPAGLIFLOZIN; PLACEBO;

CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DISEASE COURSE; END STAGE RENAL DISEASE; HUMAN; KIDNEY DISEASE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK REDUCTION;

EID: 84994098400     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1611290     Document Type: Letter

References (1)

1. Food and Drug Administration. FDA briefing document: Endocrine and Metabolic Drug Advisory Committee meeting. June 28, 2016 (http://www .fda .gov/ downloads/ AdvisoryCommittees/ CommitteesMeetingMaterials/ Drugs/ EndocrinologicandMetabolic DrugsAdvisoryCommittee/ UCM508422 .pdf).